PRTA News Alert Prothena Corporation Plc (PRTA) 22.89 02/13/2015

New Post Public Reply Private Reply Replies (0) Message Board

Feb 14, 2015 at 12:42 AM

Prothena Corporation Plc (PRTA) 22.89 $PRTA

Alkermes Reports Positive Data on Multiple Sclerosis Drug - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Feb 10, 3:20PM CST
Alkermes (ALKS) reported positive top-line data from an early-stage study on its experimental multiple sclerosis treatment, ALKS 8700.
BIIB: 391.66 (-0.45), OPHT: 51.11 (+0.12), PRTA: 22.89 (+0.13), ALKS: 71.40 (-1.89)

AMAG's Q4 Loss Narrows Y/Y, Reiterates 2015 Outlook - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Feb 10, 9:30AM CST
AMAG Pharmaceuticals (AMAG) reported a fourth-quarter 2014 loss of 2 cents per share, narrower than the year-ago loss of 17 cents per share.
OPHT: 51.11 (+0.12), AMAG: 41.49 (+0.23), PRTA: 22.89 (+0.13)

OncoMed Starts Dosing in Non-Small Cell Lung Cancer Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Feb 05, 3:20PM CST
OncoMed Pharmaceuticals (OMED) initiated patient dosing in a phase II study (DENALI) on its experimental cancer treatment, demcizumab, being evaluated for the treatment of patients with first-line advanced-stage non-small cell lung cancer.
OMED: 26.06 (+0.30), LLY: 70.56 (+0.03), PRTA: 22.89 (+0.13), CELG: 115.88 (+0.16)

Capture Growth With Baskets Of Biotechs: LifeSci Advisors' Andrew McDonald
Life Sciences Report - Seeking Alpha - Thu Feb 05, 2:18PM CST
Andrew McDonald believes investors fundamentally underestimate the risk of investing in companies with drugs in development. To address the inherent hazards, McDonald cofounded LifeSci Advisors, which creates exchange-traded funds to limit risk. In...
PCYC: 163.28 (+0.23), IDRA: 4.10 (-0.14), INFI: 15.13 (+0.55), PRTA: 22.89 (+0.13)

Proteon Therapeutics (PRTO) Jumps: Stock Adds 6.2% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Feb 05, 8:11AM CST
Proteon Therapeutics Inc (PRTO) was a big mover last session, as the company saw its shares rise over 6% on the day.
PRTA: 22.89 (+0.13), PRTO: 10.45 (unch)

Myriad Genetics Q2 Earnings, Revenues Beat; Fall Y/Y - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Feb 04, 8:58AM CST
Although Myriad's (MYGN) second-quarter fiscal 2015 results beat the Zacks Consensus Estimate on both the top and bottom line fronts, on a year-over-year basis, both the figures declined substantially.
ACAD: 34.21 (+0.37), MYGN: 34.03 (+0.40), OPHT: 51.11 (+0.12), PRTA: 22.89 (+0.13)

Illumina Tops Q4 Earnings on Solid Revenues, Margin Growth - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jan 28, 8:30AM CST
Illumina's (ILMN) full year 2014 adjusted earnings came in at $2.74 per share, beating the Zacks Consensus Estimate by 3.4% and reflecting an improvement of 52.2% from the year-ago quarter's equivalent figure.
OPHT: 51.11 (+0.12), ILMN: 198.54 (+1.81), PRTA: 22.89 (+0.13), RGDO: 1.17 (+0.02)

Prothena (PRTA) Shares March Higher, Can It Continue? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Jan 27, 8:24AM CST
Prothena (PRTA) Shares March Higher, Can It Continue?
PRTA: 22.89 (+0.13)

3 Stocks Poised for Eye-Popping Gains in 2015
George Budwell, The Motley Fool - Motley Fool - Sat Dec 27, 6:27AM CST
Source: Flicker via 401kcalculator.org The stock market has been on fire since the start of 2012. Biotech companies, though, have posted particularly impressive gains, markedly outperforming the broader markets during this time period. The ...
OREX: 5.55 (+0.10), GILD: 101.90 (+1.10), VVUS: 2.68 (+0.13), IBB: 323.46 (+3.04), ABBV: 58.05 (+1.00), PRTA: 22.89 (+0.13), ARNA: 4.55 (+0.02)

Prothena Corp. (PRTA) Looks Good: Stock Moves Up 5.7% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Dec 22, 7:51AM CST
Prothena Corporation plc (PRTA) was a big mover last session, as its shares rose almost 6% on the day.
BIIB: 391.66 (-0.45), PRTA: 22.89 (+0.13)

After Hour Gainers / Losers
Seeking Alpha - at Seeking Alpha - Mon Dec 15, 4:37PM CST

NOW: 77.55 (+1.60), WIT: 14.18 (+0.27), AG: 6.08 (+0.17), DGII: 10.31 (+0.16), BBEP: 7.85 (+0.32), NGD: 3.73 (-0.04), IAG: 2.23 (-0.08), VIIX: 41.82 (-0.49), PRTA: 22.89 (+0.13), CDE: 7.27 (+0.07)

Prothena mAb Fast Track'd for AL Amyloidosis
Seeking Alpha - at Seeking Alpha - Mon Dec 15, 4:05PM CST

PRTA: 22.89 (+0.13)

Prothena Receives FDA Fast Track Designation for NEOD001, a Monoclonal Antibody for the Treatment of Patients With AL Amyloidosis
GlobeNewswire - Mon Dec 15, 3:10PM CST
-- First Investigational Immunotherapy for AL Amyloidosis to Receive FDA Fast Track Designation
PRTA: 22.89 (+0.13)

Commit To Purchase Prothena Corp At $17.50, Earn 33.1% Annualized Using Options
at The Street - Fri Dec 12, 10:45AM CST
Investors considering a purchase of Prothena Corp plc shares, but tentative about paying the going market price of $17.97/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put...
PRTA: 22.89 (+0.13)

First patient enrolled in Acorda Phase 3 PD trial
Seeking Alpha - at Seeking Alpha - Wed Dec 10, 7:06AM CST

IPXL: 39.51 (+0.69), ADMS: 16.98 (+0.03), TEVA: 56.77 (-0.58), ACOR: 36.14 (-0.51), PRTA: 22.89 (+0.13), NDRM: 10.76 (+0.22)

Prothena to Present at the Oppenheimer 25th Annual Healthcare Conference in New York
GlobeNewswire - Mon Dec 08, 4:11PM CST
Prothena Corporation plc (Nasdaq

RTA), a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel antibodies for the potential treatment of diseases that involve amyloid or cell adhesion, announced that Tran Nguyen, the Company's Chief Financial Officer, will be presenting at the Oppenheimer 25 Annual Healthcare Conference on Thursday, December 11, 2014, at 10:55 AM EST. The conference will be held at the Crowne Plaza Hotel in New York.
PRTA: 22.89 (+0.13)

Prothena Corporation (PRTA) Falls: Stock Goes Down 5% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Dec 04, 7:37AM CST
Shares of Prothena Corporation (PRTA) fell over 5% on the day. This continues the most recent downtrend for PRTA, as the stock is down over 9% since Nov 28. Although this slump was obviously disappointing the company has seen positive revisions and its current year loss consensus has narrowed over the past few weeks.
BIIB: 391.66 (-0.45), ANIP: 62.69 (-0.43), PRTA: 22.89 (+0.13), AFFX: 11.45 (+0.02)

Prothena Initiates NEOD001 Global Phase 3 Registrational Trial Based on Positive Results in Ongoing Phase 1/2 Study of NEOD001 in Patients With AL Amyloidosis
Thomson Reuters ONE - Tue Dec 02, 3:05PM CST
- New and Updated Results Show 50% Response Rate in 14 Cardiac-Evaluable Patients
PRTA: 22.89 (+0.13)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Standex's New Financial Lead: Stoddard Takes Helm

New Financial Captain Aboard Standex's Ship Alright, here's something that'll have investors nodding along with interest: Standex International has just named Samantha L. Stoddard as their incoming Chief Financial Officer and Treasurer, effective December 1, 2026. Now, Standex isn't some scrappy upstart. We're talking about a veteran manufacturer intricately working...

DOCS Faces Investor Legal Battle for Alleged Misconduct

The DOCS Predicament: Investors Facing Class Action Doximity, Inc., trading as NYSE:DOCS, finds itself in hot water again as shareholders gear up for a legal skirmish over alleged securities fraud. Schall, Brown & Schwartz LLP, the firm rallying the shareholders, has fired the opening salvo, pointing fingers at Doximity for cooking the books about their Newsfeed’s...

Costa Rican Firms Chase Growth at SIAL Paris 2026

Chasing Growth in Paris: Costa Rica's Bold Move When it comes to playing the global field, Costa Rica isn't just sitting back; they're on the move. Picture this: PROCOMER, along with 18 standout companies, landed smack dab in the grand hustle and bustle of SIAL Paris 2026. This isn't some leisurely stroll—it's a calculated sprint toward expanding their reach across...

Encompass Health: Leader in Rehabilitation Again in 2026

Pinnacle of Rehab: Encompass Health's Notable Streak You know, in a world where healthcare accolades fly around like confetti, Encompass Health Corp's persistence in being named America's Most Awarded Leader in Inpatient Rehabilitation by Newsweek for the seventh straight year is something to chew on. The fact that a record 78 of its hospitals dotted across 32 states...

LINC Lawsuit: Boardroom Stumbles Spark Investor Action

Class Action Kickoff: Lincoln's Educational Curveball No one fancies home runs when the ball’s out of sight, and that’s probably how some investors in Lincoln Educational Services Corporation (NASDAQ: LINC) are feeling right now. A group of shareholders has pulled back the curtain on what they believe are more than just administrative hiccups—allegations of...

F.N.B. Q3 2026 Earnings: Solid Growth Continues

F.N.B. Stays the Course with Strong Q3 2026 Ever heard the phrase “slow and steady wins the race?” That seems to be the mantra over at F.N.B. Corporation (NYSE: FNB) as they roll out their Q3 2026 earnings. Now, they aren't breaking any land speed records, but what they are doing is consistently stepping up their game, quarter by quarter, like clockwork. Drilling Down...

Plata Hits $1 Billion ARR in Record Digital Bank Growth

Plata Rocks the Boat with Rapid Revenue Growth When a digital bank like Plata rakes in $1 billion in Annual Recurring Revenue (ARR) within just 3.5 years, you can't just shrug it off. That's blazing fast by any standard, especially for a financial institution. Emerging from Mexico, this bank's rocket-like ascent is flinging the doors wide open for what's possible in the...

Clean Power Alliance's Bond Deal Secures $91M Savings

CPA Triumphs Yet Again With Bond Savings I'll tell you, the Clean Power Alliance (CPA) just hit the jackpot again. We're talking a $1.4 billion energy prepayment bond deal that locks in a whopping $91.1 million in savings over the next seven years. Not bad, huh? A Closer Look at the Numbers CPA's charm—besides being the top green power supplier in the U.S.—is spinning...

U.S. Millionaire Surge: Market Waves or Mirage?

Flashing Billions: Minting Millionaires at Breakneck Speed It sounds like something out of an 80s movie: every single day, over 1,200 folks in the United States become millionaires. Yep, you heard right. The UBS Global Wealth Report 2026 threw that number out, and it sure caught my attention. It's not everyday you hear about the U.S. cranking out millionaires like they're...

Ama La Vida's New Coaching: More Than a Financial Plan

Breaking the Retirement Myth Retirement ain't just about sailing off into the sunset with a fat wallet. What happens when the honeymoon period of the "golden years" ends and you're left pacing the floorboards, unsure of what comes next? Enter Ama La Vida's fresh approach to retirement coaching, tackling the side of retirement that's rarely spoken about: identity,...